Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design

27 views | Dec 28 2021

Gregory J Riely et al. described the design of PHAROS, an ongoing, open-label, single-arm, Phase II trial evaluating the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib in patients with metastatic BRAFV600-mutant NSCLC, as first- or second-line treatment. [Read the Full Post]

ZCCHC14 regulates proliferation and invasion of non-small cell lung cancer through the MAPK-P38 signalling pathway

285 views | Oct 25 2021

Xiuying Shi et al. found that ZCCHC14 could regulate proliferation and invasion of NSCLC through the P38 pathway. [Read the Full Post]

Microcystin-LR (MC-LR) Triggers Inflammatory Responses in Macrophages

307 views | Oct 24 2021

Robin C Su et al. discovered that through a high-throughput, unbiased kinase activity profiling strategy, MC-LR-induced phosphorylation events were compared with potential inhibitors, and doramapimod was found to effectively prevent MC-LR-induced inflammatory responses in macrophages. [Read the Full Post]

Immunotherapy in Hepatocellular Carcinoma

551 views | Aug 27 2021

Claudia A M Fulgenzi et al. thought that in the absence of predictive biomarkers, choice of immunotherapy over kinase inhibitors would continue to remain an empirical exercise, guided by balancing anti-tumour efficacy with toxicity considerations in the individual patient. [Read the Full Post]

Interpretable deep recommender system model for prediction of kinase inhibitor efficacy across cancer cell lines

142 views | Aug 11 2021

Krzysztof Koras et al. proposed a novel interpretability approach, which in addition to the set of modeled features consideres also the genes and processes outside of this set. [Read the Full Post]

Effects of combination treatment with transcranial magnetic stimulation and bone marrow mesenchymal stem cell transplantation or Raf inhibition on spinal cord injury in rats

133 views | Aug 10 2021

Sining Feng et al. thought that compared with monotherapy, combination therapy displayed an improved therapeutic effect on SCI by further suppressing Raf/MEK/ERK signaling. [Read the Full Post]

Effective treatment of a BRAF V600E-mutant epithelioid glioblastoma patient by vemurafenib: a case report

170 views | Jul 13 2021

Zhiying Lin et al. found that the use of BRAF inhibitors combined with inhibitors of these seven genes may be a useful remedial treatment option. [Read the Full Post]

YAP/TAZ suppress drug penetration into hepatocellular carcinoma via stromal activation

534 views | Jun 15 2021

Kyungjoo Cho et al. indicated that drug delivery into liver cancer was impaired by YAP/TAZ signaling in tumor cells and subsequent activation of stroma by the signaling. [Read the Full Post]

83JAK-STAT inhibition mediates romidepsin and mechlorethamine synergism in Cutaneous T-cell Lymphoma

127 views | Jun 07 2021

Jose R Cortes et al. found a role for romidepsin plus mechlorethamine in combination in the treatment of CTCL and uncovered a previously unrecognized role for JAK-STAT signaling in the response to romidepsin and romidepsin-based combination therapies in SS. [Read the Full Post]

Hypoxia induces chemoresistance of esophageal cancer cells to cisplatin through regulating the lncRNA-EMS/miR-758-3p/WTAP axis

171 views | Jun 04 2021

Zi-Jiang Zhu et al. uncovered a critical lncRNA-EMS/miR-758-3p/WTAP axis in regulating hypoxia-mediated drug resistance to cisplatin in EC. [Read the Full Post]